Gong Xinlei, Qin Shukui
Department of Medical Oncology, PLA Cancer Center of Bayi Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing 210002, China.
Hepatobiliary Surg Nutr. 2018 Dec;7(6):466-474. doi: 10.21037/hbsn.2018.11.04.
Hepatocellular carcinoma (HCC) is a common malignancy worldwide and is especially prevalent in the Chinese population. Treatment of advanced HCC has posed a considerable challenge to clinicians and highly effective therapies remain elusive. Angiogenesis contributes greatly to the pathogenesis, invasion and metastasis of HCC. Therefore, anti-angiogenesis therapy could be instrumental to the treatment of HCC. In recent years, several anti-angiogenesis drugs have generated significant outcomes in a few key clinical studies, and in this light, anti-angiogenesis therapy has become a critical aspect of comprehensive treatment of HCC. In this article, to provide a reference for clinicians, we review these advances and discuss the future direction of development.
肝细胞癌（HCC）是全球常见的恶性肿瘤，在中国人群中尤为普遍。晚期HCC的治疗给临床医生带来了巨大挑战，高效的治疗方法仍然难以捉摸。血管生成在HCC的发病机制、侵袭和转移中起很大作用。因此，抗血管生成治疗可能有助于HCC的治疗。近年来，几种抗血管生成药物在一些关键临床研究中取得了显著成果，鉴于此，抗血管生成治疗已成为HCC综合治疗的关键方面。在本文中，为临床医生提供参考，我们回顾这些进展并讨论未来的发展方向。
